Impact investors are re-evaluating mental health as more than a social concern and increasingly as a viable investment sector — but turning need into a credible commercial proposition requires clear evidence, scale and regulatory rigour, according to participants in a recent expert discussion organised by German consultancy FASE.
From silent cost to investable vertical
Speakers at the FASE event argued that mental health has been an under-recognised drag on economies because issues often “run silently in the background” until they lead to staff departures and reduced productivity. That background effect, they said, translates into measurable losses for employers and national economies.
Yet views differ on whether and how mental health fits into conventional impact investing. Some investors treat it as a deeply investable vertical — one firm represented at the discussion has dedicated an entire impact fund to the area — while others remain cautious, saying projects must meet the same commercial and clinical thresholds expected in healthcare generally.
What investors are looking for
Speakers identified a consistent set of criteria that ventures need to satisfy to be considered credible investment cases. These include:
- Scalable business models capable of reaching large populations or health systems;
- Robust clinical evidence demonstrating safety and effectiveness;
- Regulatory compliance that allows products or services to be integrated into mainstream care pathways;
- A team and execution plan able to deliver the solution at scale in complex healthcare markets.
As one experienced angel investor and mentors put it during the discussion:
“My initial due diligence is quick: I always ask myself if the startup has an idea that the world really needs and a team that can execute it.”
Barriers beyond business models
Founders described additional barriers rooted in clinical culture and public perception. According to one co‑founder who spoke at the event, mental health therapies are still sometimes stigmatised within medical settings, and there is scepticism among some clinicians and patients about the effectiveness of existing interventions. That scepticism, they said, motivates efforts to bring evidence‑based medical solutions to the fore.
Speakers also noted the uneven path to commercialisation for mental health innovations: while some digital and therapy models show promise, not all approaches meet the clinical and regulatory thresholds investors demand. The implication is that impact capital will flow more readily to ventures that can combine measurable health outcomes with a durable commercial model.
Scale of the problem
The dimension of the challenge underlines why investors are paying attention. Globally, around 1 billion people are estimated to be living with a mental health condition; in Europe the annual costs associated with mental health impacts were cited as exceeding €76 billion. Those figures were used by panel participants to frame mental health as both a public health and an economic issue.
| Indicator | Figure |
|---|---|
| People living with a mental health condition (global) | 1 billion |
| Annual cost in Europe | €76 billion |
Implications for policy and practice
For policymakers and health services, the growing investor interest could bring both opportunities and challenges. On one hand, private capital and innovation may accelerate the development and dissemination of new treatments or delivery models. On the other, ensuring that commercial incentives align with public health goals — and that interventions are validated by rigorous clinical data — will be essential to avoid fragmentation or inequitable adoption.
Speakers at the event pointed to examples of ventures seeking to balance impact and viability. Two impact firms discussed, Coobi and Lucoyo Health, were presented as cases that have worked to integrate clinical credibility with business models acceptable to investors, though the discussion emphasised that the route has not been straightforward.
Investors and founders alike stressed that turning the scale of need into effective, sustainable solutions depends on maintaining high standards of evidence and compliance, and on clear demonstration that interventions produce meaningful improvements for patients and for systems under strain.
